ArticleFrontiers in genetics2025
Case Report: Novel GLA mutation in a Chinese female with renal-predominant Fabry disease and cardiac hypertrophy.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by GLA gene mutations, leading to deficient α-galactosidase A (α-Gal A) activity and progressive accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3) in multiple tissues. Diagnosis remains challenging in late-onset renal-predominant phenotypes. Case description: A 72-year-old Chinese female presented with end-stage renal disease (ESRD) and hypertrophic cardiomyopathy, prompting a clinical suspicion of FD. The diagnosis was confirmed by the identification of a novel GLA missense variant, c.522T>G (p.Cys174Trp), which was classified as likely pathogenic. All tested family members who carried this variant exhibited the characteristic biochemical phenotype of reduced α-Gal A activity and elevated lyso-Gb3 levels. Conclusion: This report describes the first documented case of the GLA c.522T>G (p.Cys174Trp) variant, expanding the mutational spectrum of FD in East Asians. The coexistence of ESRD and cardiac hypertrophy should prompt clinicians to consider GLA screening, particularly in females with atypical presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.